Anavex Life Sciences Corp (AVXL)
3.41
-0.27
(-7.34%)
USD |
NASDAQ |
Apr 24, 16:00
3.405
0.00 (0.00%)
After-Hours: 20:00
Anavex Life Sciences Free Cash Flow: -29.31M for Dec. 31, 2023
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| December 31, 2023 | -29.31M |
| September 30, 2023 | -27.78M |
| June 30, 2023 | -25.98M |
| March 31, 2023 | -25.38M |
| December 31, 2022 | -26.53M |
| September 30, 2022 | -24.24M |
| June 30, 2022 | -27.87M |
| March 31, 2022 | -28.34M |
| December 31, 2021 | -26.01M |
| September 30, 2021 | -30.38M |
| June 30, 2021 | -28.96M |
| March 31, 2021 | -25.49M |
| December 31, 2020 | -23.43M |
| September 30, 2020 | -21.29M |
| June 30, 2020 | -17.57M |
| March 31, 2020 | -21.02M |
| December 31, 2019 | -20.09M |
| September 30, 2019 | -18.53M |
| June 30, 2019 | -20.05M |
| March 31, 2019 | -14.63M |
| December 31, 2018 | -13.12M |
| September 30, 2018 | -12.58M |
| June 30, 2018 | -10.72M |
| March 31, 2018 | -11.61M |
| December 31, 2017 | -9.484M |
| Date | Value |
|---|---|
| September 30, 2017 | -9.017M |
| June 30, 2017 | -8.689M |
| March 31, 2017 | -7.938M |
| December 31, 2016 | -9.143M |
| September 30, 2016 | -9.237M |
| June 30, 2016 | -8.807M |
| March 31, 2016 | -8.013M |
| December 31, 2015 | -6.781M |
| September 30, 2015 | -4.227M |
| June 30, 2015 | -3.710M |
| March 31, 2015 | -3.240M |
| December 31, 2014 | -2.918M |
| September 30, 2014 | -2.662M |
| June 30, 2014 | -2.229M |
| March 31, 2014 | -1.302M |
| December 31, 2013 | -1.083M |
| September 30, 2013 | -0.7776M |
| June 30, 2013 | -0.545M |
| March 31, 2013 | -0.7515M |
| December 31, 2012 | -0.7364M |
| September 30, 2012 | -1.693M |
| June 30, 2012 | -2.364M |
| March 31, 2012 | -3.331M |
| December 31, 2011 | -3.806M |
| September 30, 2011 | -3.802M |
Free Cash Flow Range, Past 5 Years
-30.38M
Minimum
Sep 2021
-17.57M
Maximum
Jun 2020
-24.64M
Average
-25.49M
Median
Mar 2021
Free Cash Flow Benchmarks
| Ventyx Biosciences Inc | -167.04M |
| Checkpoint Therapeutics Inc | -47.59M |
| Vertex Pharmaceuticals Inc | 3.279B |
| Sarepta Therapeutics Inc | -588.34M |
| NovaBay Pharmaceuticals Inc | -4.15M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -7.318M |
| Cash from Financing (Quarterly) | 0.059M |
| Free Cash Flow Per Share (Quarterly) | -0.0892 |
| Free Cash Flow Yield | -10.64% |